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Antimicrobial susceptibility was determined in 15 epidemiologically unrelated clinical isolates of Acineto-
bacter genospecies 3. Moreover, the mechanisms of resistance to some b-lactam antibiotics may be associated
with the presence of a chromosomal cephalosporinase, AmpC, and the resistance to quinolones related to
mutations in the gyrA and parC genes.
The genus Acinetobacter has a complex history, and it has
long been difficult to find phenotypic criteria for speciation
(R. E. Weaver and L. A. Actis, Letter, J. Clin. Microbiol. 32:
1833, 1994). Since 1986, this genus has been shown to consist
of at least 23 genospecies which can be identified by DNA-
DNA hybridization (4, 6, 18).
Genospecies 1, 2, 3, and 13 (18) have been shown to be
closely genetically related and difficult to separate phenotypi-
cally. Therefore, they are known as the A. calcoaceticus-A. bau-
mannii complex (6). Except for Acinetobacter genospecies 1,
which plays little or no role as a human pathogen, the remain-
ing genospecies in this complex are all important nosocomial
pathogens able to cause infections and spread in hospitals (1,
6, 8).
Although some reports have been published about the an-
timicrobial susceptibility of these genospecies, mainly A. bau-
mannii (7, 9, 16, 17, 19, 21), there are no reports concerning
the mechanisms of resistance to antimicrobial agents in Acin-
etobacter genospecies 3. Thus, we herein analyze the antimi-
crobial susceptibility and mechanisms of resistance to b-lactam
antibiotics and quinolones in 15 epidemiologically unrelated
clinical isolates of Acinetobacter genospecies 3.
In November 2000, all the isolates of A. baumannii from
clinical samples were collected in 28 hospitals around Spain. A
total of 244 strains of Acinetobacter spp. were collected: 226
A. baumannii, 15 Acinetobacter genospecies 3, and 3 unidenti-
fied Acinetobacter strains. These species were identified by am-
plified ribosomal DNA restriction analysis. Acinetobacter geno-
species 3 was also identified by sequencing the 16S rRNA gene
(20). To our knowledge, no commercial identification system
can completely discriminate within the A. calcoaceticus-A. bau-
mannii complex (2). Thus, no reactions besides growth at 44°C
would discriminate between A. baumannii and genospecies 3.
However, while Acinetobacter genospecies 3 strains are re-
ported not to grow at 44°C, exceptions to this rule do occur (6).
In fact, we found that 46.6% (7 of 15 isolates) of the studied
strains of genospecies 3 grew at 44°C.
A microdilution assay following the guidelines established by
the NCCLS (12) was used to determine the MICs of the fol-
lowing antimicrobial agents: ampicillin, piperacillin, cephalo-
thin, cefoxitin, gentamicin, amikacin, tobramycin, tetracycline,
minocycline, doxycycline, rifampin, colistin (Sigma, Madrid,
Spain), ceftazidime (GlaxoSmithKline, Uxbridge, United King-
dom), cefepime, (Bristol-Myers Squibb, Madrid, Spain), sul-
bactam and azithromycin (Pfizer, Sandwich, United Kingdom),
imipenem (Merck, Hoddesdon, United Kingdom), meropen-
em (AstraZeneca, Macclesfield, United Kingdom), cipro-
floxacin (Bayer, Leverkusen, Germany), and cotrimoxazole
(Galloso, Madrid, Spain). The breakpoints used were those
recommended by the NCCLS for nonfermentative bacteria
(12).
Table 1 shows the MICs of the different antimicrobial
agents. The antibiotics with the best activity against this species
of Acinetobacter were ceftazidime, ampicillin-sulbactam, mero-
penem, imipenem, amikacin, tetracycline, doxycycline, and
minocycline. Cephalothin, cefoxitin, ampicillin, rifampin, and
azithromycin showed the least activity. Our results agree with
those of other studies reporting the high level of susceptibility
of this species to most antimicrobial agents (1, 7, 9, 16, 19, 24,
25).
Interestingly, Houang et al. (9) described some cases of
resistance of Acinetobacter genospecies 3 to imipenem, amika-
cin, gentamicin, ceftazidime, rifampin, sulbactam, and cotri-
moxazole. Antibiotics with poor activity against A. baumannii
(21), such as tetracycline, ciprofloxacin, ceftazidime, and gen-
tamicin, showed good activity against Acinetobacter genospe-
cies 3. Therefore, when a highly antibiotic-susceptible clinical
isolate is identified as A. baumannii, it may be suspected to be
another species of Acinetobacter; thus, further genetic identi-
fication should be performed, since a correct identification is
necessary for surveillance and epidemiological studies.
To study the mechanisms of resistance to b-lactam antibiot-
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ics, the presence of TEM, OXA 1-4-like, OXA 2-3-like, OXA
5-7-like (59-TATATTCCAGCATCAACATT-39 and 59-ATG
ATGCCCTCACTTGCCAT-39), and OXA 20-37-like b-lacta-
mases, AmpC chromosomal cephalosporinase, and integrons
by PCR with primers and conditions previously described (3, 5,
13). The determination of the b-lactamase isoelectric point was
performed as described by Mathew et al. (10). The results of
the isoelectric focusing assay showed the production of a b-lac-
tamase with a pI of .8 in the 15 strains. Neither OXA-type or
TEM-type b-lactamases nor integrons of type 1 were amplified
by PCR in any strain. However, when specific primers were
used for the AmpC gene of A. baumannii, a PCR product was
obtained for all the studied strains (data not shown), suggest-
ing that the expression of this AmpC cephalosporinase, prob-
ably of chromosomal origin, may play a role in the resistance to
some b-lactam antibiotics, although other concomitant mech-
anisms of resistance cannot be discarded.
The MICs of ampicillin and ceftazidime were also deter-
mined in either the absence or the presence of 4 mg of
Syn2190/ml (5), known to inhibit chromosomal AmpC b-lac-
tamases, including that of A. baumannii (5, 14). This inhibitor
did not affect the MICs of ampicillin and ceftazidime in Acin-
etobacter genospecies 3. These results may suggest either the
presence of possible genetic differences between the AmpC
b-lactamases of A. baumannii and Acinetobacter genospecies 3
or the presence of marked differences between the membrane
permeability of both species of the complex.
Regarding quinolone resistance, PCR amplification of the
QRDR sequence produced by the gyrA and parC genes was
undertaken by using the primers and following the conditions
previously described (22, 23). The EMBL accession numbers
for the gyrA and parC genes of Acinetobacter genospecies 3
are AY204699 and AY204702, respectively. Only one strain
(AC060) was resistant to quinolones and presented a substitu-
tion of Ser for Leu in positions 83 of GyrA and 80 of ParC.
These results agree with previous reports for A. baumannii, in
which mutations in both the gyrA and parC genes are required
to obtain high levels of fluoroquinolone resistance (22, 23).
The MICs of nalidixic acid (Sigma) were also determined in
either the absence or the presence of 20 mg of Phe-Arg-b-
naphthylamide (MC207,110; Sigma) per ml (15), an efflux
pump inhibitor. The MIC of nalidixic acid decreased at least
fourfold in 60% (9 of 15) of the isolates (Table 2). According
to these results, it may be suggested that, similar to A. bau-
mannii (15), genospecies 3 possesses an efflux pump inhibited
by MC207,110 that is able to pump nalidixic acid out of the
cell. This decrease in nalidixic acid accumulation may provide
a basal level of resistance to this antimicrobial agent in this
Acinetobacter species.
In summary, we have described the antimicrobial suscepti-
bility and the mechanisms of resistance to b-lactam antibiotics
and quinolones in 15 clinical isolates of Acinetobacter genospe-
cies 3. Our results suggest that, in spite of the high level of
susceptibility to most antimicrobial agents, the percentage of
isolates resistant to ampicillin, cephalothin, and cefoxitin is
high. On the other hand, the resistance to quinolones is asso-
ciated with mutations in both the gyrA and parC genes and, in
the case of nalidixic acid, with the concomitant expression of
an efflux system.
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TABLE 1. Distribution of antibiotic susceptibilities for isolates








Ampicillina 8–128 32 128 66.7
Piperacillin 32–512 32 64 6.7
Cephalothina 256 256 256 100
Cefoxitina 128–256 128 256 100
Ceftazidime 1–8 8 8 0
Cefepime 1–32 4 16 6.7
Sulbactama,b 1–8 1 2 0
Ampicillin-sulbactam 1–4 2 2 0
Imipenem 0.12–1 0.12 0.5 0
Meropenem ,0.5–2 ,0.5 1 0
Nalidixic acida 4–1,024 8 16 6.7
Ciprofloxacin ,0.5–32 ,0.5 1 6.7
Gentamicin ,1–16 ,1 4 6.7
Tobramycin 0.25–8 0.5 8 0
Amikacin 0.5–16 1 4 0
Tetracycline ,1–4 ,1 4 0
Doxycycline ,0.5 ,0.5 ,0.5 0
Minocycline ,1 ,1 ,1 0
Azithromycina 0.5–64 4 64 20
Rifampinc 2–16 4 8 66.7
Cotrimoxazole ,0.5–2 ,0.5 1–2 0
Colistinb 0.25–2 1 2 0
a The breakpoints used for ampicillin, cephalothin, cefoxitin, sulbactam, nali-
dixic acid, and azithromycin were those recommended by the NCCLS for Enter-
obacteriaceae (12).
b The breakpoints used for colistin and sulbactam were those described by
MENSURA (11). For colistin, $4 (resistant); for sulbactam, $32 (resistant).
c Neisseria meningitidis and Haemophilus spp. are the only gram-negative bac-
teria for which the NCCLS gives interpretative criteria for rifampin, these being
MIC # 1mg/ml (susceptible) and MIC $ 4mg/ml (resistant) (12).
d MIC50, MIC at which 50% of the isolates were inhibited.
e %R, percent resistant isolates.
TABLE 2. MICs of nalidixic acid in the absence and in the




MICs of nalidixic acid (mg/ml) Level of
affectationWithout Ia With I
14 8 4 23
20 16 2 83
21 16 2 83
52 8 2 43
56 4 2 23
60 1,024 128 83
65 8 4 23
67 16 2 83
69 4 2 23
90 16 8 23
103 4 2 23
109 8 2 43
128 16 2 83
195 8 2 43
243 8 2 43
a I, Phe-Arg-b-naphthylamide.
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